These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11329414)

  • 1. Adderall for obsessive-compulsive disorder.
    Albucher RC; Curtis GC
    Am J Psychiatry; 2001 May; 158(5):818-9. PubMed ID: 11329414
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.
    Horrigan JP; Barnhill LJ
    J Clin Psychiatry; 2000 Jun; 61(6):414-7. PubMed ID: 10901338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphetamine salt compound treatment for adults with attention deficit hyperactivity disorder.
    Newcorn JH
    Curr Psychiatry Rep; 2002 Apr; 4(2):85-6. PubMed ID: 11914167
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
    Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report.
    King J; Dowling N; Leow F
    Australas Psychiatry; 2017 Apr; 25(2):178-180. PubMed ID: 27683657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing stimulant medication for attention-deficit/hyperactivity disorder.
    Wender EH
    Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute psychostimulant challenge in primary obsessive-compulsive disorder.
    Joffe RT; Swinson RP; Levitt AJ
    J Clin Psychopharmacol; 1991 Aug; 11(4):237-41. PubMed ID: 1680885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.
    Grcevich S; Rowane WA; Marcellino B; Sullivan-Hurst S
    J Child Adolesc Psychopharmacol; 2001; 11(1):35-41. PubMed ID: 11322743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology.
    Faraone SV; Pliszka SR; Olvera RL; Skolnik R; Biederman J
    J Child Adolesc Psychopharmacol; 2001; 11(2):171-80. PubMed ID: 11436957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to comments by Gonzalez et al. on the CONCERTA, Adderall XR Food Evaluation (CAFE) study.
    Auiler JF; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2003; 19(1):64-5. PubMed ID: 12661783
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study.
    Faraone SV; Short EJ; Biederman J; Findling RL; Roe C; Manos MJ
    Int J Neuropsychopharmacol; 2002 Jun; 5(2):121-9. PubMed ID: 12135536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adderall: the newest available option in ADHD.
    Adv Nurse Pract; 1997 Jun; 5(6):73-4. PubMed ID: 9459934
    [No Abstract]   [Full Text] [Related]  

  • 17. Paroxetine and obsessive-compulsive disorder.
    Kaye NS; Dancu C
    Am J Psychiatry; 1994 Oct; 151(10):1523. PubMed ID: 8092350
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.
    Spencer T; Biederman J; Wilens T; Faraone S; Prince J; Gerard K; Doyle R; Parekh A; Kagan J; Bearman SK
    Arch Gen Psychiatry; 2001 Aug; 58(8):775-82. PubMed ID: 11483144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adderall and other drugs for attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1994 Nov; 36(936):109-10. PubMed ID: 7968783
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and neurocognitive changes with modafinil in obsessive-compulsive disorder: a case report.
    Dittrich WH; Johansen T; Padhi AK; Smith IE; Chamberlain SR; Fineberg NA
    Psychopharmacology (Berl); 2010 Oct; 212(3):449-51. PubMed ID: 20689942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.